Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04899830
Other study ID # 2019-A02088-49
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 24, 2020
Est. completion date September 30, 2024

Study information

Verified date February 2023
Source Association APPROCHE
Contact Marie-Caroline Delebecque, CRA
Phone 0297826174
Email approche@mutualite29-56.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study focuses on the mobile robot assist device for tele-interaction: the "COVEALINK 2" robot. This telepresence robot is designed for remote use inside the home. It works with an Internet connection (Wifi or 4G). It consists of a control interface (an application installed on the smartphone or tablet of the hospitalized patient) and a mobile robot placed in the home of the hospitalized patient (composed of a mobile platform, a visualization screen whose tilt is adjustable remotely for better adaptation to the interlocutors and an audio communication system). From the app installed on his smartphone or tablet, the patient hospitalized in the center for a long time (2 months minimum) will be able to start remotely (from the center where he is hospitalized) the robot and have it move within his home to communicate with the people present at the time of use (family, friends, neighbors etc.).


Recruitment information / eligibility

Status Recruiting
Enrollment 16
Est. completion date September 30, 2024
Est. primary completion date July 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age ? 18 years old - Affiliation to a social security scheme or beneficiary of such a scheme - Having signed a free informed consent in writing - Hospitalized in PRM for a foreseeable period of at least 60 days - Living space compatible with the movement of the robot (verified by a home visit by the center's occupational therapist) and equipped with wifi - Cognitive and motor functions compatible with the use of the tablet or phone independently, with learning capabilities to use the robot and the completion of questionnaires and interviews remotely - Medically stable Exclusion Criteria: - Subject being in a period of exclusion from another protocol - Mood and behavior disorders not stabilized - Insufficient command of the French language - Protected adults (guardianship / curatorship) - Pregnant or breastfeeding women - Persons deprived of their liberty - Being unable to issue their consent - Person who has already presented a form of addiction to technologies and / or video games

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Telepresence robot
From the application installed on a tablet, the patient hospitalized in a center for a period of at least 2 months can start from the center where he is hospitalized the mobile robotic telepresence assistance device installed at home to communicate with his family, his friends, his neighbors,…)

Locations

Country Name City State
France CR Mulhouse Mulhouse Alsace
France CMRRF de Kerpape Ploemeur Bretagne
France CMPR Côte d'Amour Saint-Nazaire Pays De La Loire
France IUR Clémenceau Strasbourg Alsace

Sponsors (3)

Lead Sponsor Collaborator
Association APPROCHE COVEA, LP3C, University of Rennes 2

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of the medium-term acceptance of robotic tele-interaction Measured with hospitalized patients using questionnaires developed by the LP3C (Laboratory of Psychology, Cognition, Behavior, Communication) At 2 months
Secondary Evaluation of the a priori acceptability of robotic tele-interaction Measured with hospitalized patients using questionnaires developed by the LP3C (Laboratory of Psychology, Cognition, Behavior, Communication). Measure of the a priori acceptability on Day 0. A priori acceptability corresponds to the study of representations of the user upstream of any use of the technology. Day 0
Secondary Evaluation of the short-term acceptance of robotic tele-interaction Measured with hospitalized patients using questionnaires developed by the LP3C (Laboratory of Psychology, Cognition, Behavior, Communication). Measurement of acceptance at Day 30. The acceptance phase studies the user's judgment and impressions after the user's first interactions with the system At 1 month
Secondary Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state. This assessment is done using validated measurement scale relating to depression and anxiety: HAD scale (Hospital Anxiety and Depression). The HAD scale is an instrument used to screen for anxiety and depressive disorders. It comprises 14 items graded from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), thus making it possible to obtain two scores (maximum score for each score = 21 ).To screen for anxiety and depressive symptoms, the following interpretation is used for each of the scores (A and D): - 7 or less: no symptoms - 8 to 10: doubtful symptomatology - 11 and over: definite symptomatology. Day 0
Secondary Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state. This assessment is done using validated measurement scale relating to psychological well-being: EBEP (Psychological Well-Being Scale). The Ryff scale of psychological well-being "is constructed from six key dimensions: autonomy, mastery of the environment, personal development, positive relationships, giving meaning to one's life and acceptance of life. self. It consists of 18 items sides 1 to 6, where 6 indicating strongly agree. A high total score indicates psychological well-being. Day 0
Secondary Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state. This assessment is done using validated measurement scale relating to quality of life: questionnaire general SF-36 (Short Form 36 Healt Survey). The SF-36 questionnaire is a multidimensional questionnaire that assesses quality of life in relation to health status, regardless of causal pathology, gender, age and treatment. It assesses functioning and overall well-being using a questionnaire using 36 questions divided into 8 dimensions (physical functioning, role limitations related to physical health, physical pain, general health, vitality, functioning or social well-being, role limitations related to mental health, mental health). Day 0
Secondary Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state. This assessment is done using validated measurement scale relating to level of social participation: LHS scale (London Handicap Scale). This scale questions everyday life by assessing mobility, physical independence, occupation (work, hobbies, vacations, etc.), social integration, perception of the outside world and economic independence.
It takes the form of a questionnaire comprising 6 items rated from 0 to 1: - 1 = no handicap - 0 = maximum handicap.
Day 0
Secondary Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state. This assessment is done using validated measurement scale relating to depression and anxiety: HAD scale (Hospital Anxiety and Depression). The HAD scale is an instrument used to screen for anxiety and depressive disorders. It comprises 14 items graded from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), thus making it possible to obtain two scores (maximum score for each score = 21 ).To screen for anxiety and depressive symptoms, the following interpretation is used for each of the scores (A and D): - 7 or less: no symptoms - 8 to 10: doubtful symptomatology - 11 and over: definite symptomatology. At 2 months
Secondary Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state. This assessment is done using validated measurement scale relating to psychological well-being: EBEP (Psychological Well-Being Scale). The Ryff scale of psychological well-being "is constructed from six key dimensions: autonomy, mastery of the environment, personal development, positive relationships, giving meaning to one's life and acceptance of life. self. It consists of 18 items sides 1 to 6, where 6 indicating strongly agree. A high total score indicates psychological well-being. At 2 months
Secondary Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state. This assessment is done using validated measurement scale relating to quality of life: questionnaire general SF-36 (Short Form 36 Healt Survey). The SF-36 questionnaire is a multidimensional questionnaire that assesses quality of life in relation to health status, regardless of causal pathology, gender, age and treatment. It assesses functioning and overall well-being using a questionnaire using 36 questions divided into 8 dimensions (physical functioning, role limitations related to physical health, physical pain, general health, vitality, functioning or social well-being, role limitations related to mental health, mental health). At 2 months
Secondary Measure the effects of the use of the telepresence device on the patient's perception of his environment and his psycho-thymic state. This assessment is done using validated measurement scale relating to level of social participation: LHS scale (London Handicap Scale). This scale questions everyday life by assessing mobility, physical independence, occupation (work, hobbies, vacations, etc.), social integration, perception of the outside world and economic independence.
It takes the form of a questionnaire comprising 6 items rated from 0 to 1: - 1 = no handicap - 0 = maximum handicap.
At 2 months
Secondary Evaluation of the a priori acceptability of robotic tele-interaction for users, relatives and members of the multidisciplinary team Measurement with categories of users around the patient and members of the multidisciplinary team, using questionnaires developed by the LP3C (Laboratory of Psychology, Cognition, Behavior, Communication). Measurement of a priori acceptability on Day 0. A priori acceptability corresponds to the study of representations of the user upstream of any use of the technology. Day 0
Secondary Evaluation of the medium-term acceptance of robotic tele-interaction for users, relatives and members of the multidisciplinary team Measurement with categories of users around the patient and members of the multidisciplinary team, using questionnaires developed by the LP3C (Laboratory of Psychology, Cognition, Behavior, Communication). Measurement of acceptance at Day 60. The acceptance phase studies the user's judgment and impressions after the user's first interactions with the system. At 2 months
See also
  Status Clinical Trial Phase
Recruiting NCT06086951 - Pai.ACT - An Artificial Intelligence Driven Chatbot Assisted ACT N/A
Completed NCT04361149 - Motor Unit Abnormalities After Experimentally Induced Sensitization Phase 4
Completed NCT04681235 - Virtual Reality Training Affects on Motor Functions and Mental Health in Stroke Patients N/A
Recruiting NCT04620707 - RGS@Home: Personalized 24/7 Home Care Post-stroke N/A
Completed NCT04619953 - Cognitive-motor Dual Task Training in Patients With Multiple Sclerosis N/A
Completed NCT04684173 - A Preliminary Study on Artificial Intelligence for Infant Motor Screening
Recruiting NCT05637775 - DiSCIoser: Improving Arm Sensorimotor Functions After Spinal Cord Injury Via Brain-Computer Interface Training N/A
Active, not recruiting NCT03114748 - Electroencephalographic Monitoring in Patients Treated by Deep Brain Stimulation N/A
Completed NCT05373394 - Evaluation of Cognitive and Motor Neurological Disorders in the Short and Long Term After Surgery for the Removal of a Diffuse Low-grade Glioma of the Supplementary Motor Area
Recruiting NCT05511207 - Clinical Validation of a Hybrid BCI-controlled FES for Upper Limb Rehabilitation After Stroke N/A
Recruiting NCT06392802 - Effectiveness of a Rehabilitation Exercise Plan at Home to Treat Post-stroke Patients in the Chronic Phase N/A
Recruiting NCT05872737 - FAB Programme for Parents of Children With NDD N/A
Not yet recruiting NCT05900310 - Linus Health CDS Retrospective Validation Study
Completed NCT02828813 - Neural Mechanisms of Motor and Cognitive Networks
Completed NCT02821598 - Effects of the Proprioceptive Neuromuscular Facilitation for Promoting Muscular Irradiation N/A
Recruiting NCT05183152 - Non-invasive BCI-controlled Assistive Devices N/A
Recruiting NCT05349539 - Instrumental Assessment of Motor Symptoms by Means of Wearable Sensors in Patients With Parkinson's Disease
Terminated NCT05316519 - Transcutaneous Auricular Vagus Nerve Stimulation to Enhance Motor Learning N/A
Completed NCT04203589 - Explorer Babies Early Intervention Program N/A
Completed NCT02816541 - Effects of Pilates-based Therapeutic Exercises on the Postural Control N/A